Blunted inflammatory response in STEMI patients timely reperfused

Journal of Cardiovascular Medicine

Volumn 15, Issue 1, 2014, Pages 48-52

  Brunetti, Natale Daniele ^a   Correale, Michele ^a   De Gennaro, Luisa ^a   Cuculo, Andrea ^a   Pellegrino, Pier Luigi ^a   Di Biase, Matteo ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

C reactive protein; inflammation; ST elevation acute myocardial infarction; timely reperfusion

Indexed keywords

AGED; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RISK FACTORS; THROMBOLYTIC THERAPY; TIME FACTORS; TIME-TO-TREATMENT; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84894090059     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328365c13a     Document Type: Article

References (17)

1. Brunetti ND, Troccoli R, Correale M, et al. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol 2006; 109:248-256.
2. Cusack MR, Marber MS, Lambiase PD, et al. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 2002; 39:1917-1923.
3. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108:135-142.
4. Tsakiris AK, Marnelos PG, Nearchou NS, et al. The influence of thrombolytic therapy on C-reactive protein in ST-segment elevation acute myocardial infarction. Hellenic J Cardiol 2006; 47:218-222.
5. Brunetti ND, Munno I, Pellegrino PL, et al. Inflammatory cytokines imbalance in the very early phase of acute coronary syndrome: correlations with angiographic findings and in-hospital events. Inflammation 2011; 34:58-66.
6. Brunetti ND, Munno I, Pellegrino PL, et al. Inflammatory cytokine imbalance after coronary angioplasty: links with coronary atherosclerosis. J Interv Cardiol 2007; 20:248-257.
7. De Sutter J, De Buyzere M, Gheeraert P, et al. Fibrinogen and C-reactive protein on admission as markers of final infarct size after primary angioplasty for acute myocardial infarction. Atherosclerosis 2001; 157:189-196.
8. Hoffmann R, Suliman H, Haager P, et al. Association of C-reactive protein and myocardial perfusion in patients with ST-elevation acute myocardial infarction. Atherosclerosis 2006; 186:177-183.
9. Amasyali B, Kose S, Kilic A, et al. C-reactive protein on admission and the success of thrombolytic therapy with streptokinase: is there any relation? Int J Cardiol 2003; 92:27-33.
10. Karadag B, Vatan B, Hacioglu Y, et al. Serum myeloperoxidase level predicts reperfusion in patients with myocardial infarction receiving thrombolytic therapy. Heart Vessels 2009; 24:247-253.
11. Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000; 102:2329-2334.
12. Akbulut M, Kutlu M, Ozbay Y, et al. Efficacy of clopidrogel on reperfusion and high-sensitivity C-reactive protein in patients with acute myocardial infarction. Mediators Inflamm 2009; 2009:932515.
13. Merlini PA, Cugno M, Rossi ML, et al. Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol 2004; 93:822-825.
14. Blancke F, Claeys MJ, Jorens P, et al. Systemic inflammation and reperfusion injury in patients with acute myocardial infarction. Mediators Inflamm 2005; 2005:385-389.
15. Michaels AD, Gibson CM, Barron HV. Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol 2000; 85 (5A):50B-60B.
16. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34:1512-1521.
17. Morishima I, Sone T, Tsuboi H, et al. Plasma C-reactive protein predicts left ventricular remodeling and function after a first acute anterior wall myocardial infarction treated with coronary angioplasty: comparison with brain natriuretic peptide. Clin Cardiol 2002; 25:112-116.